Cartesian Therapeutics Inc [NASDAQ: RNAC] closed the trading session at $7.6 on 2025-11-26. The day’s price range saw the stock hit a low of $7.23, while the highest price level was $7.605.
The stocks have a year to date performance of -59.72 percent and weekly performance of 6.29 percent. The stock has been moved at -24.00 percent over the last six months. The stock has performed -8.65 percent around the most recent 30 days and changed -26.07 percent over the most recent 3-months.
If compared to the average trading volume of 103.25K shares, RNAC reached to a volume of 143905 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Cartesian Therapeutics Inc [RNAC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RNAC shares is $35.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RNAC stock is a recommendation set at 1.44. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wedbush have made an estimate for Cartesian Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 09, 2025. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on December 19, 2024, representing the official price target for Cartesian Therapeutics Inc stock.
RNAC stock trade performance evaluation
Cartesian Therapeutics Inc [RNAC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.29. With this latest performance, RNAC shares dropped by -8.65% in over the last four-week period, additionally sinking by -24.00% over the last 6 months – not to mention a drop of -57.57% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RNAC stock in for the last two-week period is set at 44.84, with the RSI for the last a single of trading hit 0.53, and the three-weeks RSI is set at 0.60 for Cartesian Therapeutics Inc [RNAC]. The present Moving Average for the last 50 days of trading for this stock 8.76, while it was recorded at 7.35 for the last single week of trading, and 11.49 for the last 200 days.
Cartesian Therapeutics Inc [RNAC]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Cartesian Therapeutics Inc [RNAC] shares currently have an operating margin of -109.96% and a Gross Margin at 98.05%. Cartesian Therapeutics Inc’s Net Margin is presently recorded at -597.83%.
Cartesian Therapeutics Inc (RNAC) Capital Structure & Debt Analysis
Cartesian Therapeutics Inc (RNAC) Efficiency & Liquidity Metrics
Cartesian Therapeutics Inc (RNAC) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Cartesian Therapeutics Inc. (RNAC) effectively leverages its workforce, generating an average of -$4342272.73 per employee. The company’s liquidity position is robust, with a Current Ratio of 10.67% and a Quick Ratio of 13.33%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Cartesian Therapeutics Inc [RNAC] stock
With the latest financial reports released by the company, Cartesian Therapeutics Inc posted -0.59/share EPS, while the average EPS was predicted by analysts to be reported at -0.83/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.23. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RNAC. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Cartesian Therapeutics Inc go to 6.57%.
Cartesian Therapeutics Inc [RNAC]: Institutional Ownership
There are presently around $23.96%, or 59.54%% of RNAC stock, in the hands of institutional investors. The top three institutional holders of RNAC stocks are: FMR LLC with ownership of 0.51 million shares, which is approximately 0.3293%. BLACKROCK INC., holding 0.41 million shares of the stock with an approximate value of $$11.01 million in RNAC stocks shares; and BLACKROCK INC., currently with $$8.27 million in RNAC stock with ownership which is approximately 0.1975%.
